GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 12,019 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 12,019 shares of the firm’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $73.76, for a total transaction of $886,521.44. Following the transaction, the chief financial officer now directly owns 32,932 shares in the company, valued at $2,429,064.32. The trade was a 26.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, October 29th, Kevin Feeley sold 274 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $18,248.40.
• On Monday, September 9th, Kevin Feeley sold 895 shares of GeneDx stock. The shares were sold at an average price of $33.33, for a total value of $29,830.35.
• On Tuesday, September 3rd, Kevin Feeley sold 262 shares of GeneDx stock. The stock was sold at an average price of $31.71, for a total value of $8,308.02.

GeneDx Stock Performance

Shares of WGS stock opened at $80.46 on Tuesday. The firm’s 50 day moving average is $60.46 and its 200 day moving average is $40.26. The stock has a market capitalization of $2.21 billion, a P/E ratio of -25.87 and a beta of 2.11. GeneDx Holdings Corp. has a 12 month low of $1.41 and a 12 month high of $89.11. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.25. The firm had revenue of $76.90 million for the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business’s quarterly revenue was up 44.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.82) earnings per share. On average, sell-side analysts anticipate that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Institutional Investors Weigh In On GeneDx

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in GeneDx by 4.2% during the first quarter. Vanguard Group Inc. now owns 707,612 shares of the company’s stock valued at $6,460,000 after acquiring an additional 28,678 shares in the last quarter. Driehaus Capital Management LLC bought a new position in GeneDx in the 2nd quarter valued at $11,335,000. Fred Alger Management LLC purchased a new position in shares of GeneDx during the 3rd quarter valued at $16,731,000. Geode Capital Management LLC increased its holdings in shares of GeneDx by 8.7% in the third quarter. Geode Capital Management LLC now owns 377,631 shares of the company’s stock worth $16,030,000 after purchasing an additional 30,379 shares during the period. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of GeneDx in the second quarter worth $9,575,000. 61.72% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on WGS. The Goldman Sachs Group raised their target price on GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Wells Fargo & Company lifted their price objective on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. BTIG Research increased their target price on shares of GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. Craig Hallum lifted their price target on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Finally, TD Cowen increased their price objective on GeneDx from $46.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $59.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.